Abstract
Atheroma calcification is a common feature of advanced atherosclerosis, however with the advent of CT scanning it has become possible to detect extensive coronary calcification in the absence of flow-limiting lesions. While this phenomenon is known in renal disease, it also exists in some patients with exertional angina. Vascular pathology suggests biomineralisation associated with development of osteoblast-like cells in the arterial wall. While some conventional risk factors are shared with atheroma formation, others such as ethnicity and medications appear more specific to extensive calcification and may mirror those for osteoporosis. Similarly an atherogenic diet can predispose to both conditions while some elements promote or inhibit coronary calcification but not atheroma formation. The immune and endocrine systems contribute to both conditions but not necessarily in the same way, with vitamins D and K more related to calcification than atheroma formation. Finally, statins significantly lower low density lipoprotein (LDL) cholesterol and reduce atheroma formation but are largely powerless against extensive calcification. Although investigations into the exact cause of extensive coronary calcification are in their infancy, early results suggest that it is sufficiently different in nature from atheroma formation to be considered as a separate condition. Further research would yield a greater understanding, which would aid management and the development of specific biomarkers to reduce the cost and radiation risk of CT scanning.
Keywords: Atheroma, atherosclerosis, coronary calcification, biomineralisation
Current Vascular Pharmacology
Title: Extensive Coronary Calcification: A Clinically Unrecognised Condition
Volume: 8 Issue: 5
Author(s): Rachel Nicoll and Michael Henein
Affiliation:
Keywords: Atheroma, atherosclerosis, coronary calcification, biomineralisation
Abstract: Atheroma calcification is a common feature of advanced atherosclerosis, however with the advent of CT scanning it has become possible to detect extensive coronary calcification in the absence of flow-limiting lesions. While this phenomenon is known in renal disease, it also exists in some patients with exertional angina. Vascular pathology suggests biomineralisation associated with development of osteoblast-like cells in the arterial wall. While some conventional risk factors are shared with atheroma formation, others such as ethnicity and medications appear more specific to extensive calcification and may mirror those for osteoporosis. Similarly an atherogenic diet can predispose to both conditions while some elements promote or inhibit coronary calcification but not atheroma formation. The immune and endocrine systems contribute to both conditions but not necessarily in the same way, with vitamins D and K more related to calcification than atheroma formation. Finally, statins significantly lower low density lipoprotein (LDL) cholesterol and reduce atheroma formation but are largely powerless against extensive calcification. Although investigations into the exact cause of extensive coronary calcification are in their infancy, early results suggest that it is sufficiently different in nature from atheroma formation to be considered as a separate condition. Further research would yield a greater understanding, which would aid management and the development of specific biomarkers to reduce the cost and radiation risk of CT scanning.
Export Options
About this article
Cite this article as:
Nicoll Rachel and Henein Michael, Extensive Coronary Calcification: A Clinically Unrecognised Condition, Current Vascular Pharmacology 2010; 8 (5) . https://dx.doi.org/10.2174/157016110792007003
DOI https://dx.doi.org/10.2174/157016110792007003 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carbohydrate Reward and Psychosis: An Explanation For Neuroleptic Induced Weight Gain and Path to Improved Mental Health?
Current Neuropharmacology The Aromatic Stacking Interactions Between Proteins and their Macromolecular Ligands
Current Protein & Peptide Science New Anti-Anginal Drugs: Ranolazine
Cardiovascular & Hematological Agents in Medicinal Chemistry Patent Annotations
Recent Patents on Cardiovascular Drug Discovery Therapeutic Potential of microRNA Modulation in Pulmonary Arterial Hypertension
Current Vascular Pharmacology Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets Thromboxane Synthase Inhibitors and Thromboxane A2 Receptor Antagonists: A Quantitative Structure Activity Relationships (QSARs) Analysis
Current Medicinal Chemistry Gender Disparity in Lipid Target Achievements in High and Very High Atherosclerotic Cardiovascular Disease Risk Patients in the Arabian Gulf
Current Vascular Pharmacology Electrochemical MIP-Sensors for Drugs
Current Medicinal Chemistry Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Current Clinical Pharmacology Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited
Current Medicinal Chemistry Understanding eNOS for Pharmacological Modulation of Endothelial Function: A Translational View
Current Pharmaceutical Design Recent Developments in the Synthesis of Acetylcholinesterase Inhibitors
Mini-Reviews in Medicinal Chemistry ω-3 Polyunsaturated Fatty Acids Effects on the Cardiometabolic Syndrome and their Role in Cardiovascular Disease Prevention: An Update from the Recent Literature
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Understanding Genetic Factors in Idiopathic Scoliosis, a Complex Disease of Childhood
Current Genomics Frequency Domain Mapping of Atrial Fibrillation - Methodology, Experimental Data and Clinical Implications
Current Cardiology Reviews Pharmacological Treatment of Obesity: Current Standards and Future Perspectives
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cardiovascular Toxicity from the Perspective of Oxidative Stress, Electron Transfer, and Prevention by Antioxidants
Current Vascular Pharmacology Transport of Cryptotanshinone, a Major Active Triterpenoid in Salvia Miltiorrhiza Bunge Widely Used in the Treatment of Stroke and Alzheimers Disease, Across the Blood-Brain Barrier
Current Drug Metabolism Clinical and Pre-clinical Applications of the Transcendental Meditation Program® in the Prevention and Treatment of Essential Hypertension and Cardiovascular Disease in Youth and Adults
Current Hypertension Reviews